NCT01376102 - BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance) | Biotech Hunter

Enrollment

657

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Osteoporosis

Interventions

DRUG

BONVIVA(ibandronate) injection

Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Trial Locations (1)

120-752

GSK Investigational Site, Seoul